Literature DB >> 2381617

Microbiologic efficacy of intravaginal clindamycin cream for the treatment of bacterial vaginosis.

S Hillier1, M A Krohn, D H Watts, P Wolner-Hanssen, D Eschenbach.   

Abstract

Bacterial vaginosis is characterized by replacement of the normal Lactobacillus-predominant vaginal flora with Gardnerella vaginalis, anaerobic bacteria, and Mycoplasma hominis. The present study evaluated the vaginal flora of women with bacterial vaginosis before and after treatment with intravaginal clindamycin cream. Sixty-seven nonpregnant women with symptoms and signs of bacterial vaginosis, and without other genital tract infections, were randomly assigned to receive placebo cream or 0.1, 1, or 2% clindamycin cream. Quantitative vaginal cultures for facultative and anaerobic bacteria and genital mycoplasmas were performed at enrollment and at 4-7 days and 4-5 weeks after completion of therapy. At enrollment, G vaginalis was recovered from 99%, Bacteroides sp from 94%, Peptostreptococcus sp from 81%, and M hominis from 58% of the 67 women with bacterial vaginosis. The vaginal cultures yielded a median of 12 isolates per specimen, with equal numbers of aerobic and anaerobic species. The mean log concentration was 1.2 X 10(9) cfu/mL for aerobic and 2.6 X 10(8) cfu/mL for anaerobic bacteria. After treatment, the frequency and concentration of bacteria per milliliter of vaginal fluid decreased for G vaginalis, Bacteroides sp, Peptostreptococcus sp, and M hominis. The 2% clindamycin cream had the greatest effect on the bacterial vaginosis-associated flora and resulted in clinical resolution of bacterial vaginosis in 15 (94%) of 16 women. Treatment with lower concentrations of clindamycin cream had less effect on the vaginal flora and resulted in clinical cure in 25 (71%) of 35 women. Therapy was associated with an increase in the frequency and concentration of Lactobacillus, and a probably transient increase in the frequency of Escherichia coli and Enterococcus.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2381617

Source DB:  PubMed          Journal:  Obstet Gynecol        ISSN: 0029-7844            Impact factor:   7.661


  19 in total

Review 1.  Bacterial vaginosis.

Authors:  C A Spiegel
Journal:  Clin Microbiol Rev       Date:  1991-10       Impact factor: 26.132

2.  Women's experiences of general practitioner management of their vaginal symptoms.

Authors:  T C O'Dowd; S Parker; A Kelly
Journal:  Br J Gen Pract       Date:  1996-07       Impact factor: 5.386

3.  The anti-HIV microbicide candidate RC-101 inhibits pathogenic vaginal bacteria without harming endogenous flora or mucosa.

Authors:  Colleen R Eade; Amy L Cole; Camila Diaz; Lisa C Rohan; Michael A Parniak; Preston Marx; Patrick M Tarwater; Phalguni Gupta; Alexander M Cole
Journal:  Am J Reprod Immunol       Date:  2012-11-20       Impact factor: 3.886

4.  Quantitative microbiologic models for preterm delivery.

Authors:  Andrew B Onderdonk; Mei-Ling Lee; Ellice Lieberman; Mary L Delaney; Ruth E Tuomala
Journal:  J Clin Microbiol       Date:  2003-03       Impact factor: 5.948

5.  Antimicrobial susceptibilities of Gardnerella vaginalis.

Authors:  A B Kharsany; A A Hoosen; J Van den Ende
Journal:  Antimicrob Agents Chemother       Date:  1993-12       Impact factor: 5.191

6.  The treatment of bacterial vaginosis with a 3 day course of 2% clindamycin cream: results of a multicentre, double blind, placebo controlled trial. B V Investigators Group.

Authors:  I H Ahmed-Jushuf; M Shahmanesh; O P Arya
Journal:  Genitourin Med       Date:  1995-08

7.  Treatment of bacterial vaginosis with a three day course of 2% clindamycin vaginal cream: a pilot study.

Authors:  J Dhar; O P Arya; D J Timmins; S Moss; S Mukembo; A B Alawattegama; O Williams
Journal:  Genitourin Med       Date:  1994-04

8.  Longitudinal study of the biotypes of Gardnerella vaginalis.

Authors:  A M Briselden; S L Hillier
Journal:  J Clin Microbiol       Date:  1990-12       Impact factor: 5.948

9.  High levels of Gardnerella vaginalis detected with an oligonucleotide probe combined with elevated pH as a diagnostic indicator of bacterial vaginosis.

Authors:  D Sheiness; K Dix; S Watanabe; S L Hillier
Journal:  J Clin Microbiol       Date:  1992-03       Impact factor: 5.948

Review 10.  Evaluation and management of vaginitis.

Authors:  P L Carr; D Felsenstein; R H Friedman
Journal:  J Gen Intern Med       Date:  1998-05       Impact factor: 5.128

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.